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LIST OF ABBREVIATIONS 
 
BDG: -D-Glucan 
CMV: cytomegalovirus 
HT: heart transplantation 
IR: incidence rate 
IS: immunosuppression 
KT: kidney transplantation 
LT: liver transplant 
LuT: lung transplantation 
MMF: mycophenolate mofetil 
mTORi: inhibitors of the mammalian target of rapamycin 
NA: not applicable 
OKT3: monoclonal antibody targeted at the CD3 receptor 
PJP: Pneumocystis jirovecii pneumonia 
PTY: person transplant years 
q.d.: daily 
q.w.: once a week 
SLF-PYT: sulfadoxine/pyrimethamine 
SOT: solid organ transplant 
TCMR: T cell-mediated rejection 
t.i.w.: three times a week 
TMP-SMX: Trimethoprim-sulfamethoxazole 
TRANSNET: Transplant-Associated Infection Surveillance Network 
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ABSTRACT 
 
Background: In liver transplant (LT) recipients, Pneumocystis jirovecii pneumonia (PJP) 
is most frequently reported before 1992 when immunosuppressive regimens were more 
intense. It is uncertain whether universal PJP prophylaxis is still applicable in the 
contemporary LT setting. 
 
Aims: to examine the incidence of PJP in LT recipients followed at our institution where 
routine prophylaxis has never been practiced and to define the prophylaxis strategies 
currently employed among LT units in Spain. 
 
Patients and methods: we retrospectively reviewed all LT performed at our center from 
1990 to October 2019. The identification of PJP cases was performed through the 
individual review of medical records and through microbiological and hospital discharge 
records. All 25 adult LT units in Spain were queried via email to specify their current 
prophylaxis strategy against PJP.  
 
Results: during the study period 683 LT procedures were carried out on 631 patients. 
Five cases of PJP were identified, with only one occurring within the first 6 months after 
the LT. The cumulative incidence and incidence rate were 8.2 cases per 1000 patients 
and 0.99 cases per 1000 persons transplant year. All LT units responded to our query, 
the majority of which provide prophylaxis (80%). PJP prophylaxis for the first 6 months 
was the most frequent duration reported (48%). In contrast, 20% of the centers do not 
apply prophylaxis. 
 
Conclusions: the low incidence of PJP in our unprophylaxed cohort, with most cases 
occurring beyond the usual recommended period of prophylaxis, do not support a one‐
size‐fits‐all approach to PJP prophylaxis. A significant heterogeneity in prophylaxis 
strategies exists among Spanish LT centers.  
 
Key words: Prophylaxis, Pneumocystis jirovecii, liver transplantation.  
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RESUMEN  
 
Introducción: En los receptores de trasplante hepático (TH), la neumonía por 
Pneumocystis jirovecii (PJP) era informada con mayor frecuencia antes de 1992, cuando 
los regimenes inmnosupresores que se aplicaban eran más intensos. No se sabe con 
certeza si la profilaxis universal de la PJP sigue siendo recomendable en el contexto 
actual del TH. 
Objetivos: Examinar la incidencia de PJP en los receptores de TH seguidos en nuestra 
institución donde nunca se ha llevado a cabo profilaxis frente PJP, y definir las 
estrategias de profilaxis empleadas actualmente en las distintas unidades de TH en 
España. 
Métodos: Revisamos retrospectivamente todos los TH realizados en nuestro centro 
desde 1990 hasta octubre de 2019. La identificación de los casos de PJP se llevó a cabo 
mediante la revisión individual de la historia clínica de cada paciente y a través de los 
registros del Servicio de Admisión y del Servicio de Microbiología. Las 25 unidades de TH 
de España fueron consultadas por correo electrónico para especificar su estrategia de 
profilaxis actual contra la PJP. 
Resultados: Durante el periodo de estudio se realizaron 683 TH en 631 pacientes. Se 
identificaron cinco casos de PJP, de los que solo uno ocurrió en los primeros 6 meses 
después del TH. La incidencia acumulada y la tasa de incidencia fueron de 8.2 casos por 
cada 1000 pacientes y 0.99 casos por cada 1000 pacientes trasplantados-año. Todas las 
unidades de TH respondieron a nuestra consulta, la mayoría de las cuales administran 
profilaxis (80%). La profilaxis en los primeros 6 meses fue la más frecuente (48%). En 
cambio, el 20% de los centros no la administra.  
 
Conclusiones: La baja incidencia de PJP en nuestra cohorte de pacientes sin profilaxis, 
donde la mayoría de los casos ocurrieron tras el periodo usualmente recomendado de 
profilaxis, no respalda un enfoque único para la profilaxis de la PJP. Existe una 
significante heterogeneidad entre las estrategias de profilaxis de los diferentes centros 
españoles con unidad de TH.  
Palabras clave: Profilaxis, Pneumocystis jirovecii, trasplante hepático. 
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INTRODUCTION 
 
Pneumocystis jirovecii, formerly Pneumocystis carinii, is a ubiquitous, opportunistic 
fungus that causes Pneumocystis jirovecii pneumonia (PJP) in immunocompromised 
individuals, including solid organ transplant (SOT) recipients. This infection leads to 
substantial morbidity and mortality and prior to the broad implementation of 
prophylaxis, the risk of developing PJP among SOT recipients was approximately 5-15% 
1. This figure exceeds the recommended incidence threshold of 3-5% for using 
prophylaxis 2, and accordingly, current guidelines recommend anti-PJP prophylaxis for 
at least 6-12 months for all SOT recipients due to the higher degree of 
immunosuppression during these first months 1,3-5. For lung and small bowel transplant 
recipients requiring higher intensity of immunosuppression or in case of prior PJP 
infection or cytomegalovirus infection, guidelines recommend considering prolonged 
prophylaxis1. Trimethoprim-sulfamethoxazole (TMP-SMX) is the prophylactic drug of 
choice with two meta-analysis reporting a reduction in the risk of PJP occurrence of 85-
91% in non-human immunodeficiency virus immunocompromised patients when 
compared to no prophylaxis 2,6.  
 
The evidence supporting the use of anti-PJP prophylaxis in liver transplant (LT) 
recipients, however, is less clear. PJP incidence varies with the type of organ 
transplanted, the geographic region, the immunosuppressive regimen utilized, and the 
period studied 1. The high incidences of PJP in the absence of prophylaxis reported in LT 
cohorts from the 1980´s 7,8 contrast with those from recent series in which PJP incidence 
is below 3%  9-13 and even similar to incidences from LT recipients using prophylaxis 14-24 
(Table 1). Moreover, only one study concerning LT patients was included in the two 
meta-analysis reporting the efficacy of TMP-SMX prophylaxis, and this randomized 
clinical trial did not include a control group without prophylaxis as it assessed the 
efficacy and safety of weekly sulfadoxine/pyrimethamine compared with daily TMP-
SMX 17. These data question the risk-benefit ratio of a systematic PJP prophylaxis in LT 
recipients and may lead to variability in prophylactic strategies among centers. Little 
data are available in this latter regard and, to our knowledge, are restricted to pediatric 
SOT setting 25,26.  
 
In this report, we aim to examine the incidence and characteristics of PJP in LT recipients 
followed at our transplant center where routine prophylaxis is not practiced since the 
beginning of our LT program in 1990 and to define the prophylaxis strategies currently 
employed for PJP prevention among LT units in Spain.  
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AIMS 
 
The object of the present study is to examine the incidence and characteristics of PJP in 
LT recipients followed at our institution where routine prophylaxis has never been 
practiced and to define the prophylaxis strategies currently employed among LT units in 
Spain. 
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MATERIAL AND METHODS 
Patients 
The Marques de Valdecilla University Hospital (Santander, Cantabria, Spain) is an urban, 
academic tertiary care center with great expertise in organ transplantation. We 
conducted a retrospective review regarding PJP infection of all LT performed at our 
institution since the beginning of our adult LT program in November 1990 to October 
2019. In the initial years our center performed all LT, not only from Cantabria, but also 
from several others Spanish autonomous communities such as Galicia, Basque Country, 
Canary Islands, Asturias, La Rioja and Castilla y Leon. These regions progressively 
developed their own LT programs over the following 12 years, and since 2009 our 
program is responsible of all LT performed in Cantabria and La Rioja. The organ donation 
activity in these two Spanish autonomous communities is the highest of our country 
(above 80 donors per million of population), and as of January 1, 2019, their combined 
population was 895,212 inhabitants. All patients received an ABO-compatible primary 
orthotopic LT from deceased donors using the piggyback operation 27 and no prophylaxis 
against PJP was undertaken, except for some patients with combined liver-kidney 
transplant.  
In order to evaluate the local prevalence of PJP infection in other solid organ transplant 
(SOT) recipients at our institution, a retrospective review regarding this infection was 
also conducted in recipients of kidney (KT), heart (HT), and lung transplantation (LuT). 
The KT program was the first type of SOT to be performed at our center in February 26, 
1975. At its beginning, it covered all the transplant activity from several Spanish regions 
(Cantabria, Castilla y Leon, Asturias and Basque Country), but currently this activity is 
restricted to Cantabria. However, the program still undertakes all combined kidney-
pancreas transplants from Asturias, Basque Country, and La Rioja and KT in 
hyperimmunized patients from several other regions. Universal anti-PJP prophylaxis 
with TMP-SMX for 6 months is performed in all KT recipients since 1996. The HT program 
began in December 17, 1984. It has one of the highest HT rates of the country and 
performs all HT from various Spanish regions (Cantabria, Basque Country, and La Rioja). 
No prophylaxis against PJP is applied. Finally, the LuT program began in March 29, 1997. 
It currently covers all the LuT activity from Cantabria, Asturias, Basque Country, Navarra, 
La Rioja, and several provinces of Castilla y Leon (Palencia, León, Valladolid, Burgos, 
Salamanca and Zamora). Lifelong prophylaxis against PJP with TMP-SMX is established 
in all LuT recipients since the beginning of the program.  
 
Cases 
 
PJP cases were defined by the following criteria: (1) new onset of respiratory symptoms; 
2) radiological findings consistent with PJP infection (Figure 1); 3) microbiological 
demonstration of PJP infection (i.e. Real-time quantitative PCR, and/or Grocott 
methenamine silver stain performed in samples from bronchial alveolar lavage (BAL), 
sputum (spontaneous or induced), and transbronchial or open lung biopsy) (Figure 2). 
Cases without microbiological confirmation were also included if the clinical and 
radiological picture supported the diagnosis of PJP. Information on demographics, 
indication for LT, time period between LT and PJP, diagnostic method, clinical 
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presentation, treatment and outcome of PJP, co-existing infections, immunosuppressive 
regimens used at PJP diagnosis, and previous acute or chronic rejection were retrieved 
for all LT patients.  
The identification of PJP cases was performed using three approaches: 1) Individual 
review of the medical records of each LT recipient; 2) List of all laboratory-confirmed PJP 
cases from the Department of Microbiology; 3) Hospital discharge records. The latter 
consisted of a list of all patients admitted to our hospital with diagnosis upon discharge 
of PJP registered as code 136.3 of the International Classification of Diseases, Ninth 
Revision, Clinical Modification, listed in any position in the Hospitalization Minimum 
Data Set, that is the National database of hospital discharge records in Spain. These 
microbiological and discharge records were cross-referenced by medical record number 
against a secure intramural database of all LT recipients transplanted at our center. The 
search of PJP cases in the other SOT recipients did not include the individual review of 
their medical records and was limited to data obtained from the microbiological and 
discharge records, and also from each SOT database.  
 
Immunosuppressive drug regimens in liver transplantation 
From 1990 to 1999, postoperative immunosuppression was based on triple therapy with 
cyclosporine A, azathioprine and steroids. In subsequent years tacrolimus replaced 
cyclosporine as first-line therapy due to its better long-term graft and patient survival 
28. Similarly, mycophenolate mofetil (MMF) replaced azathioprine as the antimetabolite 
agent of choice and it was generally used for treatment of T cell-mediated rejection 
(TCMR) and/or for patients who had renal dysfunction limiting the dose of tacrolimus. 
The remaining patients received dual therapy with tacrolimus and steroids. The latter 
were tapered slowly during the first year at the beginning of the program and 
hereinafter were discontinued 4–6 months post-LT, except for those patients at higher 
immunological risk (e.g. immune-mediated diseases such autoimmune hepatitis). 
Inhibitors of the mammalian target of rapamycin (mTORi) were generally used in case 
of intolerance to MMF and/or development of de novo malignancy after LT. In the last 
decade, induction therapy with the interleukin-2 receptor blockers (basiliximab) was 
given as a calcineurin-sparing agent to patients with prior or postoperative significant 
renal impairment (i.e. creatinine clearance <60 mL/min). Long-term 
immunosuppression was adjusted to the recipient characteristics, etiology of primary 
liver disease and magnitude of alloimmune activation, with the aim of minimizing 
immunosuppression as much as possible. In the event of moderate and severe TCMR, 
management consisted of pulses of steroids (typically 1 g of methylprednisolone daily 
for 3 days) and an increase in calcineurin inhibitor therapy with or without addition of 
other agents (antimetabolites or mTORi). Mild TMCR was generally treated by increasing 
calcineurin inhibitor therapy.  
The study protocol conformed to the ethical guidelines of the 1975 Declaration of 
Helsinki as reflected in a priori approval by the Ethics Committee for Clinical Research of 
Cantabria. A waiver of informed consent was provided since the study was considered 
a retrospective review. 
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Prophylaxis strategies against Pneumocystis jirovecii in Spanish liver transplants units 
All the 25 adult LT units in Spain were queried via email to specify their current 
prophylaxis strategy against PJP: drug of choice, dosage, and duration.  
 
Statistical analysis  
Quantitative variables were expressed as median and interquartile range and qualitative 
variables as proportions. Cumulative incidence was determined by the number of new 
PJP cases during the study period divided by the size of the population at risk (i.e. 
patients transplanted) per 1000. Incidence rate of PJP was determined in units of the 
reciprocal of person transplant years (PTY) calculated through April 2019, death, or loss 
to follow-up. Statistical analysis was performed with IBM SPSS Statistics v22.0 for Mac 
(IBM Corp., Armonk, NY, United States).  
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RESULTS 
Incidence of Pneumocystis jirovecii in liver transplant recipients 
From November 1990 to October 2019, 683 LT procedures were carried out on 631 
patients. The most frequent liver disease and indication of LT was alcoholic liver disease 
and decompensated cirrhosis, respectively. Fifty-two patients were re-transplanted and 
29 received other transplants, the most frequent of which was combined kidney-liver 
transplantation (Table 2). Prophylaxis against PJP was established in 21 of these 29 
recipients of other additional transplants (20 KT and one bone marrow transplantation) 
following the corresponding protocols of each program. All of them were given TMP-
SMX and none developed PJP. The other patient who received a bone marrow 
transplantation died early after the third day and no prophylaxis was undertaken, 
whereas the reason for not initiating prophylaxis in the remaining KT patients could not 
be clarified after reviewing the medical record.  
In the whole LT cohort five cases of PJP were identified, giving an overall cumulative 
incidence of 7.9 cases per 1000 patients and an incidence rate of 0.95 cases per 1000 
PTY. Excluding the 21 patients in whom prophylaxis was undertaken, the cumulative 
incidence and incidence rate were 8.2 cases per 1000 patients and 0.99 cases per 1000 
PTY, respectively. 
 
Clinical presentation and outcome of Pneumocystis jirovecii infection in liver 
transplant recipients 
The risk factors for PJP, clinical features, treatment and outcome of the five LT patients 
that developed PJP are shown in Table 3.  Of the five patients only one was diagnosed 
within the first 6 months post LT and in two the infection occurred several years after 
LT. Three cases were diagnosed in the 1990´s and had more intense immunosuppressive 
regimens following the common practice at that time. Pulse steroid therapy for 
moderate/severe TCMR preceded PJP in two cases and co-existing infections were 
present in all but one patient. The most frequent symptom and radiological finding were 
fever with productive cough and ground glass opacities, respectively. In two cases no 
microbiological confirmation could be achieved, and diagnosis was based on clinical and 
radiological findings after discarding other etiologies. In another patient a lung biopsy 
was needed in order to rule out everolimus-induced interstitial lung pneumonitis. PJP 
was severe in two patients, causing death in one of them. All but one patient with severe 
pancytopenia were treated with TMP-SMX. 
 
Pneumocystis jirovecii in other solid organ transplant recipients  
Table 4 shows the number of transplants, cumulative incidence and outcome of PJP 
infection in each type of SOT. KT had the highest cumulative incidence with 8.8 cases 
per 1000 patients. Eight of the 14 KT recipients had been transplanted before the 
implementation of universal prophylaxis with TMP-SMX for the first 6 months in 1996. 
In these patients, PJP infection was diagnosed within 6 months in five of them (62.5%). 
From this period onwards, only one of the 6 cases of PJP (16.7%) was diagnosed within 
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this time frame. Mortality was high regardless of the duration of time since KT. Only one 
PJP case was identified in LuT and HT, with a cumulative incidence of 1.6 and 1.4 cases 
per 1000 patients, respectively. The LuT patient received prophylaxis with pentamidine 
due to sulfonamide allergy. Both cases occurred within the first 6 months and could be 
successfully treated. 
 
Prophylaxis strategies against Pneumocystis jirovecii in Spanish liver transplants units 
All 25 adult LT units in Spain responded to our query (Figure 3), the majority of which 
provide PJP prophylaxis (80%). All of these centers reported TMP-SMF as their drug of 
choice and all use the same dosage, 160 mg of TMP and 800 mg of SMX (i.e. double 
strength) orally three times weekly.  Duration of PJP prophylaxis, however, varied, with 
the administration of TMP-SMF for the first 6 months being the most frequent duration 
reported (n=12, 48%). In contrast, five centers (20%) do not indicate prophylaxis against 
PJP. All of them argued a perceived low incidence of PJP infection at their institution as 
the primary reason for not employing PJP prophylaxis.  
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DISCUSSION  
In liver transplant recipients, PJP is most frequently reported before 1992 when 
immunosuppressive regimens were more intense 7,8. As these regimens have evolved 
over time, it is uncertain whether universal PJP prophylaxis is still applicable in the 
contemporary LT setting. The results of the present study show, in the largest 
unprophylaxed LT cohort published to date, a very low incidence of PJP over a 30-year 
period, with most cases occurring beyond 6 months and during the first decade of the 
program when higher immunosuppression was prescribed. The survey to LT units in 
Spain indicates that while anti-PJP prophylaxis with TMP/SMX is generally implemented 
in most centers, there is a wide degree of variability within that practice, and there is 
also an increasing number of centers that do not apply prophylaxis. 
The low incidence of PJP in our cohort is in line with recent series in which this infection 
occurred in less than 3% of LT recipients in the absence of prophylaxis 9-13. These figures 
are below the recommended threshold for establishing anti-PJP prophylaxis in SOT 
patients 1,2, suggesting that previously reported attack rates, on which the current 
practice of PJP prophylaxis is based, may have lost validity due to less aggressive 
immunosuppression regimens and to improvements in the quality of the pre- and post-
transplant patient care. Two of our cases occurred far beyond the first year which is in 
agreement with increasing reports of late-onset PJP 23,24. Both of them had risk factors 
for its development, which include low total and CD4+ lymphocyte counts, 
cytomegalovirus infection, hypogammaglobulinemia, graft rejection, and patient age 
1,8,23. These risk factors, however, do not provide an accurate individual risk assessment 
and in order to decrease the morbidity of this infection but also to avoid unnecessary 
chemoprophylaxis because of its associated toxicity well-standardized criteria to 
establish PJP prophylaxis are most needed. Local PJP prevalence should also be taken 
into account when assessing this risk, as outbreaks of PJP may occur in nosocomial 
settings, possibly due to person-to-person spread 1,13. Our data support a negligible 
nosocomial transmission at our institution given the absence of outbreaks and the low 
PJP incidence in the other SOT. 
This change in the epidemiology of PJP in LT recipients may lead to different prophylactic 
strategies among transplant centers. Based on the responses of our survey, there is a 
lack of consistent or unified approach across LT units in Spain. In line with current 
guidelines, most of the centers (80%) employ universal anti-PJP prophylaxis, but there 
is large variability regarding its duration, with a trend towards a shorter period of 
treatment. This is not surprising as duration of prophylaxis has relied on expert 
consensus and not on high quality evidence 1. All these centers used the same drug and 
dosage, TMP-SMF (160 mg / 800 mg) three times weekly. The most striking finding was 
that 20% of the units did not prescribe prophylaxis due to a perceived low incidence of 
PJP infection at their institutions.  
The main limitations of our study are related to its retrospective design and to the fact 
that we do not provide risk factors to better identify patients at high risk for PJP. Our 
low incidence, however, makes this latter analysis unreliable. Given the thorough 
examination and the non-restrictive case definition for PJP (we included patients 
without microbiological confirmation) we believe in the accuracy of the reported 
incidence among LT recipients. Nevertheless, we acknowledge this incidence might be 
underestimated in the other SOT patients as the identification of PJP cases was based 
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solely on administrative and microbiological records. It must be highlighted, however, 
that these sources proved to be acceptably reliable since they identified 80% of PJP 
cases in LT recipients. Finally, we did not investigate the impact of our strategy on the 
occurrence of infections caused by other opportunistic agents sensitive to TMP-SMF 
(e.g. Toxoplasma gondii or Nocardia) 1. 
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CONCLUSIONS  
In conclusion, our findings demonstrate both a low incidence of PJP in our 
unprophylaxed transplant cohort, with infection occurring in most cases beyond the 
usual recommended period of prophylaxis, and a significant heterogeneity among 
prophylaxis strategies across Spanish LT centers. These data do not support a one‐size‐
fits‐all approach to PJP prophylaxis and call for new studies that allow for a better 
characterization of high risk PJP groups in whom prophylaxis should be implemented. 
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FIGURES 
 
 
 
 
 
 
Figure 1. A. PA chest radiograph shows Pneumocystis pneumonia manifesting with 
diffuse bilateral heterogeneous opacities. B. Axial HRCT of a patient with Pneumocystis 
pneumonia shows diffuse bilateral ground‐glass opacities on a background of reticular 
opacities (the so‐called crazy‐paving pattern).  
*Images obtained via STATdx 
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Figure 2. Diagnostic specimens for microbiological demonstration of Pneumocystis 
jirovecii infection. A. Lung biopsy showing intraalveolar proteinaceous exudates with 
the presence of numerous Pneumocystis jiroveci cysts. Grocott methenamine silver stain 
(at x400 magnification). B. Induced sputum showing the presence of numerous 
Pneumocystis jiroveci cysts. Grocott methenamine silver stain (at x100 magnification). 
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Figure 3. Prophylaxis strategies against Pneumocystis jirovecii in all liver transplant 
units in Spain.  
All centers indicating prophylaxis used trimethoprim-sulfamethoxazole (160 mg / 800 
mg) three times weekly irrespective of the prophylaxis duration. Black dots indicate the 
location of the other liver transplant units in Spain, whereas the bigger white dot 
indicates our center in Santander (Cantabria). 
* One center indicates trimethoprim-sulfamethoxazole prophylaxis only in patients with 
human immunodeficiency virus infection and another center indicates it in the rare 
cases in which anti-thymocyte polyclonal antibodies are used (1 case out of the last 200 
liver transplants at this center).  
** These two centers maintain prophylaxis for 12 months if steroids are not stopped at 
3 months in one center and at 6 months in the other. Otherwise, prophylaxis is stopped 
at 6 months. 
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TABLES 
 
 
Table 1. Large studies evaluating the incidence of Pneumocystis jirovecii in liver transplant recipients in the presence or absence of prophylaxis * 
Author and 
year 
N Study period 
and type 
Prophylaxis Cumulative 
incidence (%) 
Mortality 
(%) 
Comments 
Kusne et al, 
1988 7 
101 
1984-1985 
Prospective 
No 10.9 27.3 
All cases occurred within the first 6 months and the three deaths had 
simultaneous CMV infection. IR 10 per 1000 PTY 
Hayes et al, 
1994 8 
154 
1986-1992 
Retrospective 
No 5.2 12.5 
All cases occurred within the first 6 months. Profile of high-risk patients: 1 
episode of rejection, OKT3 treatment, or allograft dysfunction. 
Wade et al, 
1995 9 
284 
1990-1993 
Prospective 
No 0.7 0 Both cases occurred within the first 3 months. 
Hadley et al, 
1995 14 
124 
1990-1992 
Retrospective 
Since July 1991, TMP-SMX q.d.  0 NA No prophylaxis before July 1991 
Singh et al, 1997 
15 
130 
1989-1995 
Prospective 
TMP-SMX q.d. indefinitely 0 NA All patients received tacrolimus as the primary immunosuppressive agent 
Gordon et al, 
1999 16 
265 
1987-1996 
Retrospective 
1987-1991: No 
1992-1996: TMP-SMX t.i.w. 1 year 
3.8 NS 
Cohort of 1,299 SOT patients. All but one case occurred in the first year and 
without TMP-SMX. IR 3.7 per 1000 PTY. Side effects of TMP-SMX not 
reported for LT 
Torre-Cisneros 
et al, 1999 17 
120 
NS 
RCT 
TMP-SMX q.d. (N=60) 
SLF-PYT q.w. (N=60) 
1.6 0 
The two cases occurred in the TMP-SMX group. No significant differences 
between groups. Side effects in 17-18% in each group without treatment 
discontinuation 
Neuman et al, 
2002 18 
646 
1988-1995 
Retrospective 
TMP-SMX t.i.w. until 4 weeks after 
discharge 
1.2 87.5 
Splenectomy as a risk factor. High mortality due to co-existing allograft 
dysfunction and CMV infection. No case was on prophylaxis. Side effects of 
TMP-SMX were not reported 
Akamatsu et al, 
2007 19 
180 
2000-2003 
Prospective 
TMP-SMX in 22% guided by BDG 
levels (> 40 pg/mL) 
1.1 0 
All living donor liver transplants. Low positive predictive value of BDG. All 
cases occurred within the first 6 months. Side effects of TMP-SMX in 28% 
Trotter et al, 
2008 20 
853 
1997-2007 
Retrospective 
TMP-SMX t.i.w. (first 3 months) 0 NA Side effects of TMP-SMX were not reported 
Pappas et al, 
2010 21 
378 
2001-2006 
Prospective NS 0 NA 
TRANSNET. Data shown correspond to the Surveillance Cohort. PJP 12-
month cumulative incidence of 3% in the Incidence cohort with 16,808 SOT 
(4,468 LT) 
Orlando et al, 
2010 10 
203 
2001-2008 
Retrospective 
No 0 NA The authors suggested that monotherapy IS may nullify the risk for PCP 
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Table 1. Large studies evaluating the incidence of Pneumocystis jirovecii in liver transplant recipients in the presence or absence of prophylaxis * 
Author and 
year 
N Study period 
and type 
Prophylaxis Cumulative 
incidence (%) 
Mortality 
(%) 
Comments 
Ohkubo et al, 
2012 22 
156 
NS 
Retrospective 
TMP-SMX guided by BDG levels  
(> 40 pg/mL) 
2.6 50 All living donor liver transplants during a 6-year period 
Wang et al, 
2012 11 
436 
2001-2011 
Retrospective 
No 1.2 20 All five cases occurred within the first 7 months. 
Sarwar et al, 
2013 12 
611 
2000-2012 
Retrospective 
No 1,1 71.4 Four of the 7 cases (57%) occurred within the first 7 months 
Iriart et al, 2015 
23 
345 
2004-2010 
Retrospective 
TMP-SMX t.i.w. the first 6 months 1.4 NS 
Case-control study. No case while on prophylaxis. IR 2.6 per 1000 PTY. Age, 
lymphocyte count, and CMV infection were identified as risk factors for PJP 
Desoubeaux et 
al, 2016 13 
285 
2011-2014 
Retrospective 
No 2.1 50 
Four of the six cases occurred during an outbreak of PJP pneumoniae due to 
nosocomial acquisition. Survival is only reported in these 4 patients (50%) 
Neofytos et al, 
2018 24 
567 2008-2016 
Retrospective 
354 (62.4%) received prophylaxis 0.7 NS 
Swiss Transplant cohort (2842 SOT). Three of the 4 cases in LT had received 
prophylaxis. Mean time post-LT 440 days (range 71-1163)  
* The minimun number of patients to consider large a study is 100. 
 
Abbreviations: CMV: cytomegalovirus; IR: incidence rate; PTY: person transplant-year; OKT3: monoclonal antibody targeted at the CD3 receptor; TMP-SMX: trimethoprim-sulfamethoxazole; 
q.d.: daily; NA: not applicable; t.i.w.: three times a week; SOT: solid organ transplantation; LT: liver transplantation; SLF-PYT: sulfadoxine/pyrimethamine; q.w.: once a week; IS: 
immunosuppression; BDG: -D-Glucan; TRANSNET: Transplant-Associated Infection Surveillance Network; PJP: Pneumocystis jirovecii  
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Table 2. Characteristics of LT recipients. 
 
Variable * Population (N= 631) 
Age (years) 55.1 (47.2-60.9) 
Gender (male) 467 (74.0) 
Race (Caucasian) 625 (99.0) 
Primary liver disease  
 Alcohol 294 (46.6) 
 Hepatitis C 129 (20.4) 
 Alcohol + hepatitis C 52 (8.2) 
 Hepatitis B 36 (5.7) 
 Primary biliary cholangitis 21 (3.3) 
 Autoimmune hepatitis 13 (2.1) 
 Toxic 10 (1.6) 
 Other 76 (12.0) 
Indication of liver transplantation  
 Decompensated cirrhosis 347 (55.0) 
 Hepatocarcinoma 206 (32.7) 
 Acute liver failure 35 (5.5) 
 Acute on chronic liver failure 3 (0.5) 
 Other 40 (6.3) 
Retransplant 52 (8.2) 
 Hepatic artery thrombosis        14 (26.9) 
 Recurrence of primary liver disease        10 (19.2) 
 Biliary complications       9 (17.3) 
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Variable * Population (N= 631) 
 Hepatocarcinoma     1 (1.9) 
 Other        18 (34.6) 
Other transplants  29 (4.6) 
 Renal (simultaneous/Consecutive)                      14 (2.2) / 12 (1.9) 
 Bone marrow      2 (0.3) 
 Heart      1 (0.2) 
Death 306 (48.5) 
Lost of follow up ** 34 (5.4) 
Median time of follow‐up (years) 6.5 (1.8‐13.0) 
* Quantitative variables were expressed as median and interquartile range 
and qualitative variables as absolute value (proportion). 
 
** All these lost were due to change of residence to another region and 
follow-up was undertaken by the corresponding liver transplant unit.  
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  Table 3. Risk factors, clinical features, treatment and outcome of the five LT patients with PJP 
Variable Case 1 Case 2 Case 3 Case 4 Case 5 
Age at diagnosis (years) 65.7 51.5 47.4 68.6 69.3 
Sex Male Male Male Male Male 
Race Caucasian Caucasian Caucasian Caucasian Caucasian 
Etiology of liver disease Hepatitis C Alcohol Alcohol Alcohol Alcohol 
Indication of liver transplantation Hepatocarcinoma Decomp. cirrhosis Decomp. cirrhosis Decomp. cirrhosis Decomp. cirrhosis 
MELD at transplant (points) 11 23  14 19 
Child‐Pugh at transplant (points) 5 9 7 10 10 
Re‐transplant No No No No No 
Other transplants No No No No No 
Year of liver transplantation 1995 1997 1998 2005 2015 
Time from transplantation (months) 7.6 11.1 3.0 169.4 50.4 
Body mass index (Kg/m2)   21.5 29.4 34.4 
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Variable Case 1 Case 2 Case 3 Case 4 Case 5 
Tabaquism No Former smoker Former smoker Former smoker Former smoker 
Diabetes Yes Yes Yes No No 
Chronic kidney injury No Grade 1 No No No 
HIV No No No No No 
Liver allograft cirrhosis No No No No Yes 
Autoimmune disease No No Psoriasis Graves´ disease No 
Lung disease No No No COPD No 
Splenectomy No No No No No 
Immunosuppression      
 Tacrolimus No No No No Yes 
 Cyclosporine Yes Yes Yes Yes No 
 Steroids Yes Yes Yes No No 
 Mycophenolate mofetil No No No No Yes 
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Variable Case 1 Case 2 Case 3 Case 4 Case 5 
 Azathioprine Yes No Yes No No 
 mTORi No No No Everolimus Everolimus 
Acute rejection Pre-pneumocystis No No Yes No Yes 
 Treatment of acute rejection   Pulses of steroids  Pulses of steroids 
Chronic rejection No No No Yes Yes 
Co‐existing infections Ophthalmic zoster CMV Clostridium difficile No SBP 
Symptoms      
 Fever Yes Yes Yes Yes Yes 
 Cough Dry Productive Productive No Productive 
 Dyspnea Yes Yes No No Yes 
 Thoracic pain No No No No No 
Leucocytes (x 10^3/μ) 5.5 6.2 3.8 6.2 3.0 
 Linfocytes (x 10^3/μ) 0.5 1.5 0.9 2 0.1 
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Variable Case 1 Case 2 Case 3 Case 4 Case 5 
 Polymorphonuclear (x 
10^3/μ) 
4.7 4.1 2.4 3.5 2.5 
Chest CT No No Yes Yes Yes 
Radiological findings      
 Nodules No No No No No 
 Consolidations No No Yes Yes Yes 
 Ground glass opacities Yes Yes Yes Yes Yes 
 Pleural effusions No No No No No 
Bronchoscopy No No Yes Yes Yes 
Stain Positive Negative Negative Negative Negative 
PCR No No No Positive Positive 
Lung biopsy No No No Yes No 
Treatment of Pneumocystis      
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Variable Case 1 Case 2 Case 3 Case 4 Case 5 
 Antibiotic TMP‐SMX TMP‐SMX TMP‐SMX TMP‐SMX Pentamidine 
 Corticoids Yes Yes No Yes No 
 ICU admission Yes No No No No 
Death from Pneumocystis No No No No Yes 
Abbreviations:  Decomp: decompensated; COPD; chronic obstructive pulmonary disease; HIV: human immunodeficiency virus; mTORi: 
Inhibitors of the mammalian target of rapamycin; CMV: cytomegalovirus; SBP: spontaneous bacterial peritonitis; CT: computed tomography; 
TMP‐SMX: trimethoprim‐sulfamethoxazole; PCR; polymerase chain reaction; ICU: intensive care unit. 
 
 
 
 
 
 
 
 
 
 
 
 
29 
 
Table 4. Number of transplants, cumulative incidence and outcome of PJP infection 
in each type of SOT 
Variables * Kidney 
transplant 
Lung 
transplant 
Heart 
transplant 
Number of patients 1600 ** 642 705 
Number of transplants 2085 653 720 
PJP cases 14 1 1 
Cumulative incidence (cases per 
1000 patients) 
8.8 1.6 1.4 
Time from transplant to PJP 
diagnosis (months) 
17.8  
(2.0-103.6) 
1.5 6.0 
PJP diagnosis within 6 months 6 (42.9) 1 (100) 1 (100) 
Death due to PJP 3 (21.4) 0 (0) 0 (0) 
* Quantitative variables were expressed as median and interquartile range and 
qualitative variables as absolute value (proportion). 
 
** Among these, 60 consisted of combined kidney-pancreas transplantation and 26 
combined kidney-liver transplantation. 
 
Abbreviations: PJP: Pneumocystis jirovecii. 
 
 
